O Lavie1, S Narod2, F Lejbkowicz3, S Dishon3, Y Goldberg1, O Gemer1, G Rennert4. 1. Division of Gynecology and Oncology, Carmel Medical Center and B. Rappaport Faculty of Medicine, Technion, Haifa, Israel. 2. The Centre for Research in Women's Health, Toronto, Ontario, Canada. 3. Department of Community Medicine and Epidemiology and CHS National Cancer Control Center, Carmel Medical Center and B. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. 4. Department of Community Medicine and Epidemiology and CHS National Cancer Control Center, Carmel Medical Center and B. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. Electronic address: rennert@tx.technion.ac.il.
Abstract
BACKGROUND: The frequency and characteristics of disease in individuals who concomitantly harbor pathogenic mutations in both BRCA1 and BRCA2 genes are not established. MATERIALS AND METHODS: Data were collected from the database of Clalit Health Services National Familial Cancer Consultation Service. Probands referred to this clinical service and their family members are routinely tested for the three Jewish founder mutations (BRCA1: 185delAG, 5382insC, BRCA2: 6174delT). In addition, carriers identified in a population-based cohort of all cases diagnosed with breast cancer in Israel in 1987-1988 allowed the estimation of the population frequency of this phenomenon. RESULTS: In the clinic-based series of 1191 carriers of mutations in BRCA1 or BRCA2 belonging to 567 families, 22 males and females (1.85%) from 17 different families (3.0%) were found to harbor two different mutations. These included 18 individuals (1.51%) who concomitantly carried the 185delAG BRCA1 and the 6174delT BRCA2 mutations and four individuals (0.34%) who carried the 5382insC BRCA1 and the 6174delT mutations. All individuals were heterozygote carriers and none had a double mutation of both founder mutations in the BRCA1 gene itself. Seven of the 16 double carrier women (46.7%) had a personal history of breast carcinoma, diagnosed at a mean age of 44.6, compared with 372/926 (40.2%) carriers of a single mutation diagnosed with a mean age at diagnosis of 48.1 [odds ratio (OR)=1.3, 95% confidence interval (CI) 0.4-4.0]. One case (6.7%) had a personal history of ovarian carcinoma diagnosed at the age of 53 compared with 55/926 (5.9%) of the women with single mutation (OR=1.1, CI=0.2-7.6). The frequency of double mutations in the population-based national breast cancer cohort was 2.2% of all carriers, and 0.3% of all breast cancer cases in the Ashkenazi population in the cohort. The mean age at diagnosis of breast cancer was younger in the carriers of two mutations. CONCLUSION: Double carriers of mutations in the BRCA genes are rare and seem to be carrying a similar probability of developing breast and ovarian cancers as carriers of single mutations.
BACKGROUND: The frequency and characteristics of disease in individuals who concomitantly harbor pathogenic mutations in both BRCA1 and BRCA2 genes are not established. MATERIALS AND METHODS: Data were collected from the database of Clalit Health Services National Familial Cancer Consultation Service. Probands referred to this clinical service and their family members are routinely tested for the three Jewish founder mutations (BRCA1: 185delAG, 5382insC, BRCA2: 6174delT). In addition, carriers identified in a population-based cohort of all cases diagnosed with breast cancer in Israel in 1987-1988 allowed the estimation of the population frequency of this phenomenon. RESULTS: In the clinic-based series of 1191 carriers of mutations in BRCA1 or BRCA2 belonging to 567 families, 22 males and females (1.85%) from 17 different families (3.0%) were found to harbor two different mutations. These included 18 individuals (1.51%) who concomitantly carried the 185delAGBRCA1 and the 6174delTBRCA2 mutations and four individuals (0.34%) who carried the 5382insCBRCA1 and the 6174delT mutations. All individuals were heterozygote carriers and none had a double mutation of both founder mutations in the BRCA1 gene itself. Seven of the 16 double carrier women (46.7%) had a personal history of breast carcinoma, diagnosed at a mean age of 44.6, compared with 372/926 (40.2%) carriers of a single mutation diagnosed with a mean age at diagnosis of 48.1 [odds ratio (OR)=1.3, 95% confidence interval (CI) 0.4-4.0]. One case (6.7%) had a personal history of ovarian carcinoma diagnosed at the age of 53 compared with 55/926 (5.9%) of the women with single mutation (OR=1.1, CI=0.2-7.6). The frequency of double mutations in the population-based national breast cancer cohort was 2.2% of all carriers, and 0.3% of all breast cancer cases in the Ashkenazi population in the cohort. The mean age at diagnosis of breast cancer was younger in the carriers of two mutations. CONCLUSION: Double carriers of mutations in the BRCA genes are rare and seem to be carrying a similar probability of developing breast and ovarian cancers as carriers of single mutations.
Authors: E Friedman; R Bar-Sade Bruchim; A Kruglikova; S Risel; E Levy-Lahad; D Halle; E Bar-On; R Gershoni-Baruch; E Dagan; I Kepten; T Peretz; I Lerer; N Wienberg; A Shushan; A D Abeliovich Journal: Am J Hum Genet Date: 1998-10 Impact factor: 11.025
Authors: P Tonin; B Weber; K Offit; F Couch; T R Rebbeck; S Neuhausen; A K Godwin; M Daly; J Wagner-Costalos; D Berman; G Grana; E Fox; M F Kane; R D Kolodner; M Krainer; D A Haber; J P Struewing; E Warner; B Rosen; C Lerman; B Peshkin; L Norton; O Serova; W D Foulkes; J E Garber Journal: Nat Med Date: 1996-11 Impact factor: 53.440
Authors: B Modan; E Gak; R B Sade-Bruchim; G Hirsh-Yechezkel; L Theodor; F Lubin; G Ben-Baruch; U Beller; A Fishman; R Dgani; J Menczer; M Papa; E Friedman Journal: JAMA Date: 1996-12-11 Impact factor: 56.272
Authors: Thomas S Frank; Amie M Deffenbaugh; Julia E Reid; Mark Hulick; Brian E Ward; Beth Lingenfelter; Kathi L Gumpper; Thomas Scholl; Sean V Tavtigian; Dmitry R Pruss; Gregory C Critchfield Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: Gad Rennert; Shantih Bisland-Naggan; Ofra Barnett-Griness; Naomi Bar-Joseph; Shiyu Zhang; Hedy S Rennert; Steven A Narod Journal: N Engl J Med Date: 2007-07-12 Impact factor: 91.245
Authors: David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki Journal: Hum Genet Date: 2013-07-03 Impact factor: 4.132
Authors: Yoon Ju Bang; Won Kyung Kwon; Seok Jin Nam; Seok Won Kim; Byung-Joo Chae; Se Kyung Lee; Jai Min Ryu; Jong-Won Kim; Jonghan Yu; Jeong Eon Lee Journal: Cancer Res Treat Date: 2021-10-13 Impact factor: 5.036
Authors: Magdalena Koczkowska; Monika Zuk; Adam Gorczynski; Magdalena Ratajska; Marzena Lewandowska; Wojciech Biernat; Janusz Limon; Bartosz Wasag Journal: Cancer Med Date: 2016-05-11 Impact factor: 4.452
Authors: Timothy R Rebbeck; Tara M Friebel; Nandita Mitra; Fei Wan; Stephanie Chen; Irene L Andrulis; Paraskevi Apostolou; Norbert Arnold; Banu K Arun; Daniel Barrowdale; Javier Benitez; Raanan Berger; Pascaline Berthet; Ake Borg; Saundra S Buys; Trinidad Caldes; Jonathan Carter; Jocelyne Chiquette; Kathleen B M Claes; Fergus J Couch; Cezary Cybulski; Mary B Daly; Miguel de la Hoya; Orland Diez; Susan M Domchek; Katherine L Nathanson; Katarzyna Durda; Steve Ellis; D Gareth Evans; Lenka Foretova; Eitan Friedman; Debra Frost; Patricia A Ganz; Judy Garber; Gord Glendon; Andrew K Godwin; Mark H Greene; Jacek Gronwald; Eric Hahnen; Emily Hallberg; Ute Hamann; Thomas V O Hansen; Evgeny N Imyanitov; Claudine Isaacs; Anna Jakubowska; Ramunas Janavicius; Katarzyna Jaworska-Bieniek; Esther M John; Beth Y Karlan; Bella Kaufman; KConFab Investigators; Ava Kwong; Yael Laitman; Christine Lasset; Conxi Lazaro; Jenny Lester; Niklas Loman; Jan Lubinski; Siranoush Manoukian; Gillian Mitchell; Marco Montagna; Susan L Neuhausen; Heli Nevanlinna; Dieter Niederacher; Robert L Nussbaum; Kenneth Offit; Edith Olah; Olufunmilayo I Olopade; Sue Kyung Park; Marion Piedmonte; Paolo Radice; Christine Rappaport-Fuerhauser; Matti A Rookus; Caroline Seynaeve; Jacques Simard; Christian F Singer; Penny Soucy; Melissa Southey; Dominique Stoppa-Lyonnet; Grzegorz Sukiennicki; Csilla I Szabo; Mariella Tancredi; Manuel R Teixeira; Soo-Hwang Teo; Mary Beth Terry; Mads Thomassen; Laima Tihomirova; Marc Tischkowitz; Amanda Ewart Toland; Aleksandra Toloczko-Grabarek; Nadine Tung; Elizabeth J van Rensburg; Danylo Villano; Shan Wang-Gohrke; Barbara Wappenschmidt; Jeffrey N Weitzel; Jamal Zidan; Kristin K Zorn; Lesley McGuffog; Douglas Easton; Georgia Chenevix-Trench; Antonis C Antoniou; Susan J Ramus Journal: Breast Cancer Res Date: 2016-11-11 Impact factor: 6.466